Drug Profile
XC 002
Alternative Names: XC-002Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator XyloCor Therapeutics
- Class Cardiovascular therapies; Gene therapies; Vascular disorder therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coronary artery disease
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Coronary artery disease in USA (Parenteral)
- 20 Jan 2022 XC 002 is still in preclinical trials for Coronary artery disease in USA (Parenteral) (XyloCor Therapeutics pipeline, January 2022)